Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares China Large-Cap ETF (FXI) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance

iShares China Large-Cap ETFTrade
uniQure N.V. Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

iShares China Large-Cap ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: iShares China Large-Cap ETF is far larger — about 2.7× uniQure N.V. Ordinary Shares's market cap, and iShares China Large-Cap ETF is more actively traded (21,620,520 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and uniQure N.V. Ordinary Shares for 0 Days on average.

FXIQURE
Market Cap
$3.90B$1.45B
Volume
21,620,5203,323,243
52-Week High
$41.08$70.59
52-Week Low
$31.59$9.03
Typical Hold Time
151 Days0 Days
Sector
—Health
Enterprise Value
—$707.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares China Large-Cap ETF

FXI trades at $34.17 with minimal daily movement (+0.09%). The technical picture is bearish with moving averages signaling caution, though oscillators are neutral. Recent news highlights China's economic challenges including industrial overcapacity and weak domestic consumption, while corporate profits surged 26% in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54, offering potential value amid high political risk.

FXI presents a contrarian opportunity for investors seeking China exposure at discounted valuations, but faces substantial headwinds from U.S.-China tensions and domestic economic rebalancing. The ETF's heavy financial sector weighting and state-backed monetary support provide stability, though momentum remains weak. Key risks include escalating trade protectionism and China's export control uncertainties.

uniQure N.V. Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FXI
10% Buy90% Sell
Avg holding period · 151 Days
QURE
100% Buy0% Sell
Avg holding period · 0 Days

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI →

About uniQure N.V. Ordinary Shares

uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.

Read more on QURE →